HURMGEN@EC2612A

Rongchang Biotechnology and AbbVie Sign Exclusive Licensing Agreement for RC148 and Receive Upfront Payment

Rongchang Biopharmaceutical's Drug Receives Approval for Cancer Indication

Rongchang Biotech's Vensedotin New Indication Approved

CICC Raises Forecast for Rongchang Biotech's 2026 Net Profit and Target Price

Rongchang Biotech Announces Profitable 2025 Annual Report

Rongchang Biotechnology's RC288 Receives NMPA Approval for Clinical Trials

Rongchang Biotechnology Reports Profit of 710 Million Yuan for 2025 Year

Rongchang Biotech Announces 2025 Annual Report, Reversing Loss to Profit

Rongchang Biotechnology's Veseplimab Receives New Indication Approval

REMEGEN to Release FY2025 Earnings on March 27 Pre-Market (BJT), Forecast Revenue HKD 3.316 B, EPS HKD -0.4063

Rongchang Biotech to Hold Board Meeting to Approve Annual Results and Consider Dividend Payment

Rongchang Biotechnology Expected to Turn Profit in 2025

Nomura Predicts Robust Revenue and Profit Growth for RemeGen

Rongchang Bio achieved RMB 325,105.11 million in revenue in 2025, up 89.36%, with a net profit of RMB 70,852.33 million

REMEGEN released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue HKD 1.703 B (forecast HKD 1.217 B), actual EPS HKD 2.495

REMEGEN released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue HKD 3.553 B (forecast HKD 3.316 B), actual EPS HKD 1.4099 (forecast HKD -0.4041)

Citi Reiterates Buy Rating on RemeGen, Bullish on Pipeline’s Global Potential

JPMorgan Chase Maintains Buy Rating and Target Price for RemeGen

Rongchang Biotechnology expects a net profit of 716 million RMB in 2025

Rongchang Biotech Expected to Turn Profitable in 2025

ABC MULTIACTIVE

ECHO INT HOLD

ASIA TELE-NET

ARTINI HLDG

VISION VALUES

GBG HOLDINGS

DEEPEXI TECH

BIREN TECH

LOPAL TECH

SINO-LIFE GROUP

02442

06651

09606

02575

02225

02657

09995

00290

02509

01530

EASY SMART GP(02442) rose 21.49%, with a trading turnover 53.3 Million HKD, and a year-to-date rose 109.8%. 51WORLD(06651) rose 15.21%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 37.8%. DUALITYBIO-B(09606) rose 10.81%, with a trading turnover 488.5 Million HKD, and a year-to-date rose 6.6%.

Top Gainers & Losers

EASY SMART GP

51WORLD

DUALITYBIO-B

XUANZHUBIO-B

JINHAI MED TECH

FOREST CABIN

REMEGEN

GOFINTECH QUANT

QYUNS-B

3SBIO

Top 10 HK Stock Gainers (4.15)

159992

159859

516820

512010

588860

588250

Hong Kong stocks closed higher on April 15, 2026, with the Hang Seng Index up 0.29% at 25,947.32 points and the Hang Seng Tech Index rising 1.23% to 4,911.79 points. The total market turnover was 245.588 billion Hong Kong dollars. The innovative drug sector saw significant gains, while shale gas and Foxconn stocks declined. Notable gainers included Xuanzhu Biopharmaceuticals-B (+10.5%) and Rongchang Biopharmaceuticals (+9%). Conversely, Zhihu and Xunlei fell by 8.5%.

CoinLive

Yinhua CSI Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hang Seng Index

Hang Seng TECH Index

LAOPU GOLD

JD-SW

JD.com

BABA-W

Alibaba

JD HEALTH

TRIP.COM-S

BIDU-SW

Baidu

Zhihu

Xunlei

NEW ORIENTAL-S

New Oriental EDU & Tech

TIANQI LITHIUM

GANFENGLITHIUM

Ganfeng Lithium

LI NING

RemeGen

Sunshine Guojian Pharmaceutical

Laopu Gld HK SDR 50to1

JD-SWR

BABA-WR

Alibaba HK SDR 5to1

JD HEALTH-R

Trip.com HK SDR 50to1

Trip.com

BIDU-SWR

ZHIHU-W

LI NING-R

STOCKS | Hong Kong Stocks Close Higher with Tech Sector Leading Gains

RemeGen Co. Ltd. has received approval from China's National Medical Products Administration for its antibody-drug conjugate Disitamab Vedotin, in combination with Toripalimab, as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. This marks the drug's fifth approved indication in China, supported by a Phase III trial demonstrating improved survival rates over traditional chemotherapy. The approval enhances RemeGen's position in the oncology market and expands treatment options for patients. Analysts rate RemeGen's stock (HK:9995) as a Buy with a price target of HK$124.00.

Tip Ranks

RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer

02513

02526

03636

09887

09880

06600

09966

06636

KNOWLEDGE ATLAS(02513) rose 31.94%, with a trading turnover 5.0 Billion HKD, and a year-to-date rose 687.4%. EASY SMART GP(02442) rose 31.13%, with a trading turnover 32.0 Million HKD, and a year-to-date rose 91.4%. DIAGENS-B(02526) rose 24.34%, with a trading turnover 161.2 Million HKD, and a year-to-date rose 148.7%.

KNOWLEDGE ATLAS

DIAGENS-B

JINXUN RESOURCE

LEADS BIOLABS-B

UBTECH ROBOTICS

ONEROBOTICS

ALPHAMAB-B

EXTREME VISION

Top 10 HK Stock Gainers (4.1)

REMEGEN rose 14.09%; CanSino Biologics rose 6.76%, with a transaction volume of HKD 1.376 billion; 3SBio rose 11.40%, with a transaction volume of HKD 1.235 billion; Innovent Biologics rose 6.77%, with a transaction volume of HKD 1.226 billion; BeiGene rose 7.58%, with a market capitalization of HKD 284.5 billion

HK Stock Movers Tracker

Hong Kong stock movement: REMEGEN rises 14.09%, with clear capital flow, market sentiment triggers volatility attention

08368

00399

02609

The market overview of Hong Kong stocks in the past hour shows significant fluctuations in market sentiment, with a clear divergence in capital flows. Technology and pharmaceutical stocks have become hotspots for capital chasing, especially the strong rise of STARCOIN GROUP, which has attracted a lot of short-term capital attention. Meanwhile, some individual stocks like CREATIVE CHINA have encountered sharp declines, indicating a strong differentiation in the market. Overall, short-term enthusiasm is high, with increased volatility, and investor sentiment seems to be continuously adjusting. 

In the past hour, the stock with the most significant movement is STARCOIN GROUP, which performed impressively, with an increase of 24.76%, repeatedly hitting the upper limit during the session, showing strong buying sentiment. The rapid inflow of funds has attracted numerous investors' attention to this stock in a short period, boosting the activity of related sectors. 

Strong stocks:
1. BAYZED HEALTH: up 16.75%, with recent market attention on its product line, short-term capital actively intervening.
2. JINXUN RESOURCE: up 15.78%, benefiting from rising resource prices, with market sentiment high and noticeable capital inflow.
3. MINIMAX-W: up 15.33%, with active short-term trading attracting participation from speculative funds.
4. INSILICO: up 12.05%, with a strengthening technical outlook and optimistic market sentiment regarding its future development prospects.
5. EPIWORLD: up 11.52%, with the company's recent earnings forecast sparking market discussions and rapid capital follow-up.
6. REMEGEN: up 11.17%, with the overall biotechnology sector strengthening, driving this stock's rise

CREATIVE CHINA

STARCOIN GROUP

BAYZED HEALTH

MINIMAX-W

INSILICO

EPIWORLD

DONGFANG ELEC

ILUVATAR COREX

Hong Kong Stock Movement Update: STARCOIN GROUP surges 24.76%, CREATIVE CHINA plummets 26.32%

REMEGEN rose 10.96%; Innovent Biologics rose 5.71%, with a transaction volume reaching HKD 740 million; CanSino Biologics rose 4.84%, with a transaction volume reaching HKD 616 million; 3SBio rose 6.18%, with a transaction volume reaching HKD 531 million; BeiGene rose 6.41%, with a market value reaching HKD 281.8 billion

Hong Kong stock movement: REMEGEN rises 10.96%, with performance turnaround and R&D breakthroughs boosting market confidence

03939

06693

00HSI

00700

00883

On March 30, major indices in the Hong Kong stock market pulled back simultaneously, with market risk aversion sentiment rising, leading the internet and retail sectors to fall. Tencent Holdings, Alibaba, and other heavyweights faced significant pressure, with funds rotating to resource stocks, and WANGUO GOLD GP and CHIFENG GOLD showing active trading. Macroeconomically, although there were signs of recovery, the momentum was insufficient, leading to strong short-term wait-and-see sentiment among investors, while YOFC saw a significant surge

- On March 30, Hong Kong stocks showed a collective decline, with the Hang Seng Index at 24,800.69, down by 0.61%, failing to reach previous highs from March 27.  
- Key sectors like internet content and retail experienced declines, reflecting cautious market sentiment, while only a few stocks such as Changfei Optical Fiber bucked the trend with notable gains.  
- Overall, the market's weak momentum indicates ongoing concerns about external factors, and participants are closely watching policy effects and currency fluctuations.

Market Heartbeat

WANGUO GOLD GP

CHIFENG GOLD

YOFC

TENCENT

POP MART

MEITUAN

JIAXIN INTL RES

CHINA SHENHUA

BYD COMPANY

CNOOC

XIAOMI-W

SMIC

Hang Seng Index Falls 0.87% Intraday, YOFC Surges 13% Against Trend

688331

01877

In 2025, A-share biopharmaceutical companies are gradually moving from the "cash-burning R&D" stage to a new phase of "profit realization," benefiting from improved industry prosperity and policy support. As of March 29, over 70 biopharmaceutical companies have released their earnings. Among them, 61 companies achieved profitability, 29 companies saw year-on-year positive growth in net profit attributable to the parent company, and 7 companies doubled their profits. Furthermore, companies like RemeGen and InnoCare Pharma are expected to turn losses into profits, while companies such as MicuRx and Junshi Biosciences have reduced their losses

Wallstreetcn

China Merchants CSI Biotechnology Theme ETF

InnoCare Pharma

JUNSHI BIO

Junshi Biosciences

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

INNOCARE

ChinaAMC CSI Biotechnology Theme ETF

MicuRx

Strong Growth in Innovative Drug Revenue, Biopharmaceutical Companies' Performance Shows High "Innovation" Content

REMEGEN announced its performance for the fiscal year 2025, with revenue of 3.242 billion RMB, an increase of 89.5% year-on-year. It recorded a net profit of 710 million RMB, compared to a loss of 1.468 billion RMB in the previous year, turning from loss to profit; earnings per share were 1.29 RMB. No final dividend will be distributed

AASTOCKS

"Performance" REMEGEN achieved a net profit of 710 million RMB for the entire year, turning losses into profits

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

09988

09618

09888

06809

01385

01171

On March 18th, during the Hong Kong stock market trading, the three major indices collectively strengthened, with the Hang Seng Index rising by 0.87%, indicating a moderate rebound in risk appetite. The retail sector performed well, with leading stocks like Alibaba and JD leading the gains, boosting market sentiment; however, the oil and gas sector generally retreated due to the weakening of international oil prices. Among popular stocks, Shanghai Fudan surged by 12.73%, and MINIMAX-W increased by over 23%. Investors are currently focusing on macro indicators such as unemployment rates and manufacturing PMI, with market volatility influenced by external environmental factors

- On March 18, Hong Kong's three main indices gained slightly, reflecting a modest rebound in risk appetite.  
- The Hang Seng Index rose 0.87% to 26,092.72 points, while the Hang Seng Tech and the China Enterprises Index increased by 0.36% and 0.34%, respectively, with all indices maintaining their positions within recent ranges.  
- Retail stocks surged due to consumption recovery expectations, led by Alibaba and JD.com, while oil and gas exploration faced pressure from declining international oil prices.

MONTAGE TECH

SHANGHAI FUDAN

YANKUANG ENERGY

SPDR S&P Retail ETF

VanEck Retail ETF

KraneShares 2x Long BABA Daily ETF

KraneShares 2x Long JD Daily ETF

Hong Kong stock market intraday | Hang Seng Index up 0.87%, retail sector leads with Alibaba up 3.34%

HURMGEN@EC2612A(28292.HK)

HURMGEN@EC2612A Stock Performance Chart

Top 10 HK Stock Gainers (4.15)

STOCKS | Hong Kong Stocks Close Higher with Tech Sector Leading Gains

RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer

Top 10 HK Stock Gainers (4.1)

Hong Kong stock movement: REMEGEN rises 14.09%, with clear capital flow, market sentiment triggers volatility attention